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Background: The aim of this study was to investigate age-specific incidence rates and to compare disease stage,
treatment, and survival according to age group in patients with gastric adenocarcinoma.
Methods: Gastric cancer patients treated at our hospital between 1999 and 2010 were retrospectively evaluated.
We divided the cases into two subgroups: group 1 consisted of patients older than 70 years at the time of
treatment, and group 2 included patients aged 70 years or younger. In all, 151 patients over 70 years of age and
715 patients age 70 years or younger were analyzed. Categorical and continuous variables were summarized using
descriptive statistics and compared using statistical software. Overall survival rates were estimated via the
Kaplan-Meier method.
Results: Median age at diagnosis was 58 years (range: 22 to 90 years). Between 1999 and 2002 the annual median
age for patients aged older than70 years was 9.8%, which increased to 20% between 2007 and 2010. The one-year
survival rate for patients with metastatic disease (stage IV) was 10.9% (95% CI: 8.9% to 12.9%) and 27.8% (95% CI:
17.3% to 38.2%) in groups 1 and 2, respectively (P = 0.015). The five-year survival rate for patients with
non-metastatic disease (in whom curative surgery was performed) was 15.5% (95% CI = 12% to 19%) and 26.9%
(95% CI = 25.9% to 27.9%) in groups 1 and 2, respectively (P = 0.03). There were no significant differences in
gender, tumor localization in the stomach, tumor histology, perineural invasion (PNI), lymphovascular invasion (LVI),
tumor stage, or type of surgery between the two groups. However, fewer of the patients in group 1 underwent
adjuvant treatment (P = 0.02) and palliative chemotherapy (P = 0.007) than group 2 patients that were
non-metastatic and metastatic at presentation, respectively.
Conclusions: Groups 1 and 2 were similar in terms of histopathological features and surgical modality; however,
the survival rate was lower in group 1 than in group 2. The incidence of gastric cancer was higher in the patients
older than 70 years of age. Additional randomized studies are needed to further assess the safety and clinical
benefit of chemotherapy in gastric cancer patients older than70 years of age.
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The incidence and mortality rates for most cancers are
decreasing in the United States and in other developed
Western countries [1,2]; however, cancer still accounts
for more deaths than heart disease in those aged 85
years and younger [3]. Cancer in older people has* Correspondence: deniztural@gmail.com
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The overall gastric cancer incidence and mortality
rates are decreasing worldwide, but despite the recent
decline, gastric cancer remains the fourth most com-
mon cancer and the second leading cause of cancer-
related mortality [4-6]. Moreover, the incidence of
gastric cancers increases with age, especially in the
United States, and most gastric cancer patients in
Japan are older [7,8]. The age-adjusted mortality rateis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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age [9].
The aim of the present study was to use data collected
from 886 patients in our hospital-based registry who were
treated between 1999 and 2010 to evaluate age-specific in-
cidence rates, and to compare histopathology, disease
stage, treatment modalities, and outcomes according to
age group in patients with gastric adenocarcinoma.
Methods
The study included gastric cancer patients treated at
Istanbul University’s Cerrahpaşa Medical School be-
tween 1999 and 2010. The cancer in each patient was
coded according to the International Classification of
Diseases for Oncology [10]. The cases were divided into
two subgroups based on age: group 1 consisted of
patients older than 70 years of age at the time of treat-
ment, and group 2 was composed of patients aged 70
years or younger. The patients were further categorized
into five age groups: younger than 40 years, 40 to 50
years, 50 to 60 years, 60 to 69 years, and 70 years and
older. Groups 1 and 2 were compared in terms of tumor
localization in the stomach, histopathological subtype,
age at diagnosis, disease stage, neuronal invasion, lym-
phovascular invasion (LVI), and treatment modality.
The cases were also divided into the following two sub-
groups based on anatomic localization of cancer in the
stomach: cardia cancer subgroup and non-cardia cancer
subgroup (gastric antrum, pylorus, lesser and greater
curvature of the stomach) [11]. In addition, the cases were
divided into three subgroups based on histopathological
subtype, as follows: subtype subgroup 1 included patients
with intestinal gastric cancer, subtype subgroup 2 con-
sisted of those with diffuse gastric cancer, and subtype
subgroup 3 was mixed [12]. Disease stage was determined
according to the seventh edition of the International
Union Against Cancer classification system. Stage I, II,
and III were classified as non-metastatic and stage IV was
classified as metastatic. Total gastrectomy, or subtotal gas-
trectomy and lymph node dissection was performed in all
patients with non-metastatic presentation.
In non-metastatic patients the protracted 5-fluorouracil
(5FU) infusion chemotherapy regimen was used concur-
rently with postoperative radiotherapy (RT). Five cycles of
adjuvant bolus 5FU (425 mg·m-2·d-1) and leukoverin (20
mg·m-2·d-1) as a Mayo regimen was administered on treat-
ment day 1 to day 5 every 28 days to these patients after
surgery. Bolus 5FU and leukoverin were administered on
treatment day 1 to day 4 every 28 days concurrently with
postoperative RT during the 2nd and 3rd cycles of the
planned five-cycle adjuvant chemotherapy. Radiotherapy
(RT) was administered (range: 45 to 50.4 Gy) to the tumor
bed and draining lymph nodes in cases with 2- to 3-cm
margins.Patients with positive surgical margins, incomplete
chemoradiotherapy(CRT), poor performance status
(Eastern Cooperative Oncology Group (ECOG) >2), in-
adequate renal and hepatic function, and other second
primary cancers were excluded from the study. Adjuvant
chemotherapy was administered to stage IB, II, and III
patients, and palliative chemotherapy was administered
to stage IV patients. 40.1% of patients received docetaxel
(75 mg/m2) on day 1 and cisplatinum (75 mg/m2) the
next day intravenously plus infusion 5FU (750 mg/m2)
continuously on days 1 to 5 (TCF), 30% of patients
received epirubicin (50 mg/m2), cisplatin (60 mg/m2)
and 5FU (200 mg/m2) infusion (ECF), 20.2% of patients
received bolus 5FU (425 mg/m2) plus leucovorin (20
mg/m2) on days 1 to 5 (FUFA) and 9.7% of patients
received other chemotherapy regimens for palliation in
the metastatic stage.Statistical analysis
Categorical and continuous variables were summarized
using descriptive statistics (e.g., median, range, fre-
quency, and percentage) and compared using the chi-
square and Mann-Whitney U tests, respectively. The
median age rates between 1999 and 2010 for the five age
subgroups were calculated for one-year and four-year
periods. Overall survival rates (OS) and disease-free sur-
vival (DFS) were estimated via the Kaplan-Meier
method. OS was calculated as the time from the date of
diagnosis to the time of death due to any cause, and
DFS was calculated as the time from the date of diagno-
sis to the time of recurrence. Any differences in survival
between categorical variables were tested using the log-
rank test. Based on the results of univariate analysis, we
performed multivariate analysis using a Cox propor-
tional hazard model to calculate the hazard ratio (HR)
and 95% confidence interval (CI). All analyses were per-
formed using SPSS v.15.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA) software. The level of statistical
significance was set at P <0.05.Results
The hospital-based registry included 866 cases of gastric
adenocarcinoma that were treated between 1999 and
2010. Median age at diagnosis was 58 years (range: 22 to
90 years) (57 years between 1999 and 2002, 58 years be-
tween 2003 and 2006, and 59 years between 2007 and
2010). The ratio of patients aged 60 to 70 years and
older than 70 years increased from 1999 to 2010; there-
fore, advanced age was strongly correlated with the inci-
dence of gastric adenocarcinoma (P = 0.02) (Figure 1).
Between 1999 and 2002 the annual median age for
patients older than 70 years was 9.8%, which increased
to 20% between 2007 and 2010 (P = 0.001) (Figure 2).
Figure 1 Changes in the annual median age of gastric adenocarcinoma patients shown in one-year periods between 1999 and 2010.
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localization in the stomach (cardia/non-cardia), tumor
histology, perineural invasion (PNI), lymphovascular in-
vasion (LVI), tumor stage, or type of surgery between
groups 1 and 2; however, fewer of the patients in group
1 underwent adjuvant treatment (P = 0.02) and palliative
chemotherapy (P = 0.007) than group 2 patients that
were non-metastatic and metastatic at presentation, re-
spectively. The correlation between age, and clinico-
pathological factors and treatment modalities is shown
in Table 1.
The five-year survival rate in patients with non-
metastatic presentation was 15.5% (95% CI = 12% to
19%) and 26.9% (95% CI = 25.9% to 27.9%) in groups 1
and 2, respectively (P = 0.03). The one-year survival rate
in metastatic gastric cancer patients was 10.9% (95% CI =
8.9% to 12.9%) and 27.8% (95% CI = 17.3% to 38.2%) in
groups 1 and 2, respectively (P = 0.015). The survival
curves for both groups are shown in Figures 3 and 4.
In non-metastatic patients (n = 386) univariate ana-
lysis was conducted based on age subgroup, gender,
PNI, LVI, disease stage (I, II, and III), histology sub-
type, tumor localization in the stomach, and surgicalFigure 2 Changes in the annual values rates for patients older than70
2010.method, along with whether or not the patient received
adjuvant treatment. Early-stage cancer (stage I and II)
(P = 0.001), absence of PNI (P = 0.004), absence of LVI
(P = 0.007), adjuvant treatment (P = 0.04), and age 70
years or younger (P = 0.03) were associated with better
survival rates. In metastatic patients (413) we con-
ducted univariate analysis based on age subgroup, gen-
der, histological subtype, and palliative treatment
modality, and observed that being age 70 years or
younger (P = 0.015) and undergoing palliative chemo-
therapy (P = 0.001) were associated with better survival
rates. Based on these results, we performed multivariate
analysis using a Cox proportional hazard model.
Among the non-metastatic gastric cancer patients,
those who received adjuvant treatment had a HR of 0.4
(95% CI: 0.26 to 0.6), those with PNI had an HR of
1.67 (95% CI: 1.08 to 2.78), those with LVI had an HR
of 2.8 (95% CI: 1.2 to 6.6), and those with stage III
cancer had an HR of 3.0 (95% CI: 1.57 to 5.87). Among
the patients with metastatic gastric cancer, those who
received palliative chemotherapy, as opposed to pallia-
tive care, had an HR of 0.58 (95% CI: 0.44 to 0.77) and
those older than 70 years had an HR of 1.3 (95% CI:years of age are shown in one-year periods between 1999 and
Table 1 Clinicopathological features and treatment
modalities in groups 1 and 2
Variable Group 2 (age ≤70 years ) n (%)















Diffuse adenocarcinoma 229 (32)
36 (24)
Intestinal adenocarcinoma 437 (61)
99 (66)
Mixed adenocarcinoma 49 (7)
16 (10)
Stomach localization 0.2
Proximal (cardia) 127 (17.8)
31 (19.6)


















Subtotal gastrectomy 184 (56.8)
30 (48.4)
Total gastrectomy 133 (41)
30 (48.4)
Table 1 Clinicopathological features and treatment
modalities in groups 1 and 2 (Continued)
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shown in Tables 2 and 3.
The five-year DFS rate in patients with non-metastatic
presentation was 40.1% (95% CI = 39.9% to 42.5%) and
35.6% (95% CI = 32.9% to .41.1%) in groups 1 and 2, re-
spectively (P = 0.59). Univariate analysis was conducted
based on age subgroup, gender, PNI, LVI, disease stage
(I, II, and III), histology subtype, tumor localization in
the stomach, and surgical method, along with whether
or not the patient received adjuvant treatment. Early-
stage cancer (stage I and II) (P = 0.02), absence of PNI
(P = 0.03), absence of LVI (P = 0.006), and adjuvant
treatment (P = 0.03), were associated with better DFS
rates. The DFS curves are shown in Figure 5. Based on
these results, we performed multivariate analysis using a
Cox proportional hazard model. Among the non-
metastatic gastric cancer patients, those who received ad-
juvant treatment had a HR of 0.5 (95% CI: 0.36 to 0.69),
those with PNI had an HR of 1.31 (95% CI: 1.19 to 3.11),
those with LVI had an HR of 2.1 (95% CI: 1.1 to 3.7), and
those with stage III cancer had an HR of 3.3 (95% CI:
1.67 to 5.89). The details of Cox regression analysis of
DFS are shown in Table 4.Discussion
Gastric cancer is the fourth most commonly diagnosed






























Figure 3 Five-year survival rates according to age group in patients with non-metastatic presentation.
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second leading cause of cancer-related mortality in both
men and women [13-15]. In fact, gastric cancer rates
have increased among older people in both the United
States and Japan [9,10]. In the present retrospective
study the median age at diagnosis was 58 years. When
compared with the Surveillance, Epidemiology, and End
Results (SEER) data from 1999 to 2003, the median age
in the present cohort was 14 years younger than that of
the American patients [7]. In addition, the incidence rate
in patients with a median age older than 70 years
increased by 14% during the period 1999 to 2002 and by
19.8% between 2007 and 2010. In the present study
there was no difference in histopathological features, dis-
ease stage, gender, or tumor localization in the stomach
between groups 1 and 2.
A Japanese study reported that when compared to
patients aged 70 years or younger, more of the patients
aged 70 years or older had differentiated histology and
fewer had vascular involvement, but there was no differ-
ence in disease stage, lymph node involvement, tumor
size, lymphatic involvement, or gender [16]. Nonethe-
less, an earlier study by Arai et al.[17] showed that among patients older than 85 years
of age cancer was more often localized in the lower third
of the stomach. In contrast to the present study, some
Japanese studies observed that the proportion of
differentiated-type gastric carcinoma increased with age
and histological diversity during growth [16-18], but all
of these studies were conducted in the same country
and the majority of the patients were of advanced age.
In the present study there were no significant differ-
ences in surgical procedures (total versus subtotal gas-
trostomy) between groups 1 and 2; however, a limitation
of the present study is that lymph node dissection
reports were not available, and, as such, lymph node dis-
section rates could not be compared. As compared to
group 2, fewer of the patients in group 1 with non-
metastatic presentation and metastatic presentation
received adjuvant treatment and chemotherapy, respect-
ively. Saito et al. [16] reported that fewer older patients
than patients of other age groups received chemotherapy
and lymph node dissection.
Several studies reported that advanced age was asso-
ciated with shorter survival [16,19,20], whereas others































Figure 4 One-year survival rates according to age group in patients with metastatic presentation.
Table 2 Results of Cox regression analysis of the
association between overall survival rates, and perineural
invasion, lymphovascular invasion, and disease stage in
386 patients with non-metastatic presentation




Yes 0.4 (0.26 to 0.6)
Perineural invasion 0.043
Absent 1
Present 1.67 (1.08 to 2.78)
Lymphovascular invasion 0.021
Absent 1
Present 2.8 (1.2 to 6.6)
Stage 0.001
Stage I 1
Stage II 1.4 (1.09 to 1.71)
Stage III 3 (1.57 to 5.87)
≤70 years 0.03 1
>70 years 1.27(1.17 to 1.48)
CI, confidence interval; HR; hazard ratio.
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other age groups [21,22]. In the present study the five-
year survival rate in the patients age 70 years or younger
with non-metastatic presentation was significantly better
than that in the patients who were older than 70 years,
and the one-year survival rate in the patients age 70
years or younger with metastatic presentation was sig-
nificantly higher than in the patients who were older
than 70 years. As previous reported [23-26], patients in
the present study with non-metastatic presentation, andTable 3 Results of Cox regression analysis of the
association between overall survival rates, and palliative
treatment and age at diagnosis in 413 patients with
metastatic presentation




Palliative chemotherapy 0.58 (0.44 to 0.77)
Age at diagnosis 0.04
≤70 years 1
>70 years 1.3 (1.02 to 1.7)



















Figure 5 Five-year PFS rates according to age group in patients with non-metastatic presentation.
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curative resection had worse independent prognostic
factors for survival, but those who received adjuvant
treatment had favorable prognostic factors for survival.Table 4 Results of Cox regression analysis of the
association between progression-free survival rates, and
adjuvant treatment, perineural invasion, lymphovascular
invasion, and disease stage in 386 patients with non-
metastatic presentation













Stage II 1.6 (1.1 9-1.91)
Stage III 3.3 (1.67-5.89)
CI, confidence interval; HR, hazard ratio.In patients older than age 70 years with metastatic pres-
entation and who received only palliative care (no pallia-
tive chemotherapy) there was a worse independent effect
on survival. Another limitation of the present study is
that comorbidity rates were not available and, as such,
cancer-specific survival rates in groups 1 and 2 could
not be determined.
Conclusions
The median age at diagnosis and the percentage of eld-
erly patients with gastric cancer increased between
1999 and 2010. Both the elderly and non-elderly
patients had similar histopathological features and
underwent similar surgical modalities. The elderly
patients had lower survival rates than the non-elderly
patients, but fewer of them underwent adjuvant treat-
ment and palliative chemotherapy than the non-elderly
patients. Patients with PNI and LVI who did not re-
ceive adjuvant treatment and who had advanced-stage
disease had worse independent prognostic effects on
survival than patients with non-metastatic presentation.
Lower age and palliative chemotherapy were independ-
ent favorable prognostic factors that affected the sur-
vival rates in patients with metastatic presentation. The
incidence of gastric cancer was higher in the patients
who were older than70 years. Additional randomized
studies are needed to further assess the safety and
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patients who are older than 70 years of age.
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